Adamis Pharmaceuticals (ADMP) Ramps to Session Highs on Volume
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Adamis Pharmaceuticals (NASDAQ: ADMP) pushes to the highs of the session on volume that is running 28x normal. Shares are up 19%.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Transgenomic (TBIO) Climbs to Session High, Up 35%
- EnteroMedics (ETRM) Halted on LUDP
- Investment Focus: History suggests Trump month will be stocks down, dollar up
Create E-mail Alert Related CategoriesMomentum Movers, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!